trial

A Study to Test Long-term Safety of Iclepertin in People With Schizophrenia Who Took Part in a Previous CONNEX Study

NCTId NCT05211947
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Terminated
Enrollment 1,356 (actual)
Sponsored by Boehringer Ingelheim
Primary completion 2025-02-26
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Terminated
Enrollment
1,356 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2022-03-21
Primary completion
2025-02-26
Eligibility
ALL · 18 Years · 51 Years

Interventions & indications

Drugs
Iclepertin

Sponsors

Boehringer IngelheimLead Sponsor

Sites

303 total
Anaheim, United StatesBellflower, United StatesCulver City, United StatesGarden Grove, United StatesLa Habra, United StatesLong Beach, United StatesLos Angeles, United StatesOrange, United StatesOrange, United StatesPico Rivera, United StatesSan Diego, United StatesSanta Ana, United States

Linked catalysts

1
A Study to Test Long-term Safety of Iclepertin in People With Schizophrenia Who — primary completion2025-02-26

Facts & assertions

4 sourced
Enrollment
1,356
Phase
PHASE3
Primary Completion Date
2025-02-26
Status
TERMINATED
relationships
The graph out of here
drug
Iclepertin
drug
lead_sponsor
Boehringer Ingelheim
company
indication
Schizophrenia
indication
Schizophrenia
indication